Having trouble accessing articles? Reset your cache.

I-Mab looks to fill gap in NASDAQ listings by Chinese players

I-Mab Biopharma is hoping to become only the second innovative Chinese drug developer since Zai two years ago to go public on NASDAQ.

The Shanghai-based company has proposed to raise up to

Read the full 315 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE